| UniProt ID | TYDP2_HUMAN | |
|---|---|---|
| UniProt AC | O95551 | |
| Protein Name | Tyrosyl-DNA phosphodiesterase 2 | |
| Gene Name | TDP2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 362 | |
| Subcellular Localization |
Nucleus. Nucleus, PML body. Nucleus, nucleolus. Cytoplasm. Localizes to nucleolar cavities following stress localization to nucleolus is dependent on PML protein. Cytoplasm . (Microbial infection) In case of infection by picornavirus, relocali |
|
| Protein Description | DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5' phosphate. Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase 2 (TOP2) active site tyrosine residue. The 5'-tyrosyl DNA phosphodiesterase activity can enable the repair of TOP2-induced DNA double-strand breaks/DSBs without the need for nuclease activity, creating a 'clean' DSB with 5'-phosphate termini that are ready for ligation. Thereby, protects the transcription of many genes involved in neurological development and maintenance from the abortive activity of TOP2. Hydrolyzes 5'-phosphoglycolates on protruding 5' ends on DSBs due to DNA damage by radiation and free radicals. Has preference for single-stranded DNA or duplex DNA with a 4 base pair overhang as substrate. Acts as a regulator of ribosome biogenesis following stress. Has also 3'-tyrosyl DNA phosphodiesterase activity, but less efficiently and much slower than TDP1. Constitutes the major if not only 5'-tyrosyl-DNA phosphodiesterase in cells. Also acts as an adapter by participating in the specific activation of MAP3K7/TAK1 in response to TGF-beta: associates with components of the TGF-beta receptor-TRAF6-TAK1 signaling module and promotes their ubiquitination dependent complex formation. Involved in non-canonical TGF-beta induced signaling routes. May also act as a negative regulator of ETS1 and may inhibit NF-kappa-B activation.; (Microbial infection) Also acts as a 5'-tyrosyl-RNA phosphodiesterase following picornavirus infection: its activity is hijacked by picornavirus and acts by specifically cleaving the protein-RNA covalent linkage generated during the viral genomic RNA replication steps of a picornavirus infection, without impairing the integrity of viral RNA.. | |
| Protein Sequence | MELGSCLEGGREAAEEEGEPEVKKRRLLCVEFASVASCDAAVAQCFLAENDWEMERALNSYFEPPVEESALERRPETISEPKTYVDLTNEETTDSTTSKISPSEDTQQENGSMFSLITWNIDGLDLNNLSERARGVCSYLALYSPDVIFLQEVIPPYYSYLKKRSSNYEIITGHEEGYFTAIMLKKSRVKLKSQEIIPFPSTKMMRNLLCVHVNVSGNELCLMTSHLESTRGHAAERMNQLKMVLKKMQEAPESATVIFAGDTNLRDREVTRCGGLPNNIVDVWEFLGKPKHCQYTWDTQMNSNLGITAACKLRFDRIFFRAAAEEGHIIPRSLDLLGLEKLDCGRFPSDHWGLLCNLDIIL | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 1 | Acetylation | -------MELGSCLE -------CCCHHCCC | 9.65 | 22223895 | |
| 23 | Ubiquitination | EEGEPEVKKRRLLCV HCCCCHHCHHEEEEH | 38.61 | 21906983 | |
| 23 | Sumoylation | EEGEPEVKKRRLLCV HCCCCHHCHHEEEEH | 38.61 | 28112733 | |
| 24 | Ubiquitination | EGEPEVKKRRLLCVE CCCCHHCHHEEEEHH | 48.18 | - | |
| 53 (in isoform 2) | Ubiquitination | - | 33.75 | - | |
| 54 (in isoform 2) | Ubiquitination | - | 3.53 | - | |
| 60 | Phosphorylation | EMERALNSYFEPPVE HHHHHHHHHCCCCCC | 31.86 | 28796482 | |
| 61 | Phosphorylation | MERALNSYFEPPVEE HHHHHHHHCCCCCCH | 15.76 | 28796482 | |
| 69 | Phosphorylation | FEPPVEESALERRPE CCCCCCHHHHHHCCC | 25.34 | 28555341 | |
| 82 | Ubiquitination | PETISEPKTYVDLTN CCCCCCCCCEEECCC | 48.73 | 21890473 | |
| 82 (in isoform 1) | Ubiquitination | - | 48.73 | 21890473 | |
| 82 | Sumoylation | PETISEPKTYVDLTN CCCCCCCCCEEECCC | 48.73 | 28112733 | |
| 83 | Phosphorylation | ETISEPKTYVDLTNE CCCCCCCCEEECCCC | 39.22 | 28796482 | |
| 84 | Phosphorylation | TISEPKTYVDLTNEE CCCCCCCEEECCCCC | 9.70 | 28796482 | |
| 88 | Phosphorylation | PKTYVDLTNEETTDS CCCEEECCCCCCCCC | 35.80 | 28450419 | |
| 92 | Phosphorylation | VDLTNEETTDSTTSK EECCCCCCCCCCCCC | 29.71 | 25159151 | |
| 93 | Phosphorylation | DLTNEETTDSTTSKI ECCCCCCCCCCCCCC | 31.09 | 28450419 | |
| 95 | Phosphorylation | TNEETTDSTTSKISP CCCCCCCCCCCCCCC | 31.34 | 25159151 | |
| 96 | Phosphorylation | NEETTDSTTSKISPS CCCCCCCCCCCCCCC | 37.59 | 25262027 | |
| 97 | Phosphorylation | EETTDSTTSKISPSE CCCCCCCCCCCCCCC | 31.79 | 25262027 | |
| 98 | Phosphorylation | ETTDSTTSKISPSED CCCCCCCCCCCCCCC | 28.25 | 25627689 | |
| 112 (in isoform 2) | Ubiquitination | - | 28.39 | 21890473 | |
| 114 (in isoform 2) | Phosphorylation | - | 6.02 | 27642862 | |
| 125 (in isoform 3) | Ubiquitination | - | 53.53 | 21890473 | |
| 125 (in isoform 2) | Phosphorylation | - | 53.53 | 27642862 | |
| 139 | Phosphorylation | RARGVCSYLALYSPD HHHHHHHHHHHHCCC | 7.29 | 22817900 | |
| 157 | Phosphorylation | LQEVIPPYYSYLKKR EEECCHHHHHHHHHH | 10.33 | 22817900 | |
| 158 | Phosphorylation | QEVIPPYYSYLKKRS EECCHHHHHHHHHHC | 9.16 | 22817900 | |
| 160 | Phosphorylation | VIPPYYSYLKKRSSN CCHHHHHHHHHHCCC | 13.35 | 22817900 | |
| 190 | Ubiquitination | MLKKSRVKLKSQEII EEECCCCCCCCCCCC | 49.43 | - | |
| 192 | Sumoylation | KKSRVKLKSQEIIPF ECCCCCCCCCCCCCC | 44.36 | - | |
| 192 | Ubiquitination | KKSRVKLKSQEIIPF ECCCCCCCCCCCCCC | 44.36 | 21906983 | |
| 192 | Sumoylation | KKSRVKLKSQEIIPF ECCCCCCCCCCCCCC | 44.36 | - | |
| 203 | Sumoylation | IIPFPSTKMMRNLLC CCCCCCCHHHHCEEE | 34.73 | - | |
| 203 | Sumoylation | IIPFPSTKMMRNLLC CCCCCCCHHHHCEEE | 34.73 | - | |
| 203 (in isoform 1) | Ubiquitination | - | 34.73 | 21890473 | |
| 203 | Ubiquitination | IIPFPSTKMMRNLLC CCCCCCCHHHHCEEE | 34.73 | 21890473 | |
| 203 | Acetylation | IIPFPSTKMMRNLLC CCCCCCCHHHHCEEE | 34.73 | 25953088 | |
| 220 (in isoform 2) | Ubiquitination | - | 2.93 | - | |
| 222 (in isoform 2) | Ubiquitination | - | 7.02 | - | |
| 233 (in isoform 2) | Ubiquitination | - | 20.62 | 21890473 | |
| 242 | Ubiquitination | AERMNQLKMVLKKMQ HHHHHHHHHHHHHHH | 19.73 | - | |
| 242 | Acetylation | AERMNQLKMVLKKMQ HHHHHHHHHHHHHHH | 19.73 | 25953088 | |
| 247 | Ubiquitination | QLKMVLKKMQEAPES HHHHHHHHHHHCCCC | 41.47 | 21906983 | |
| 254 | Phosphorylation | KMQEAPESATVIFAG HHHHCCCCCEEEEEC | 28.34 | - | |
| 272 (in isoform 2) | Ubiquitination | - | 23.43 | - | |
| 277 (in isoform 2) | Ubiquitination | - | 34.79 | - | |
| 289 | Ubiquitination | DVWEFLGKPKHCQYT HHHHHHCCCCCCEEE | 53.71 | - | |
| 291 | Ubiquitination | WEFLGKPKHCQYTWD HHHHCCCCCCEEEEC | 61.57 | - | |
| 319 (in isoform 2) | Ubiquitination | - | 3.36 | - | |
| 321 (in isoform 2) | Ubiquitination | - | 16.74 | - | |
| 341 | Ubiquitination | LDLLGLEKLDCGRFP CCCCCCCCCCCCCCC | 55.45 | 2063986 | |
| 371 (in isoform 2) | Ubiquitination | - | - |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 60 | S | Phosphorylation | Kinase | MAPK6 | Q16659 | GPS |
| 88 | T | Phosphorylation | Kinase | ALK4 | P36896 | PSP |
| 88 | T | Phosphorylation | Kinase | ACVR1B | Q61271 | GPS |
| 92 | T | Phosphorylation | Kinase | ALK4 | P36896 | PSP |
| 92 | T | Phosphorylation | Kinase | ACVR1B | Q61271 | GPS |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of TYDP2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of TYDP2_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| ETS1_HUMAN | ETS1 | physical | 12743594 | |
| PARK7_HUMAN | PARK7 | physical | 19023331 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND MASS SPECTROMETRY. | |
| Phosphorylation | |
| Reference | PubMed |
| "Ttrap is an essential modulator of Smad3-dependent Nodal signalingduring zebrafish gastrulation and left-right axis determination."; Esguerra C.V., Nelles L., Vermeire L., Ibrahimi A., Crawford A.D.,Derua R., Janssens E., Waelkens E., Carmeliet P., Collen D.,Huylebroeck D.; Development 134:4381-4393(2007). Cited for: INTERACTION WITH ACVR1B AND SMAD3, PHOSPHORYLATION AT THR-88 ANDTHR-92, AND MUTAGENESIS OF THR-88 AND THR-92. | |